Ken SHORTMAN, WEHI, Melbourne, AUS «Enhancing protective antibody responses by
targeting vaccine antigens to Clec9A on dendritic cells» Host:...
Not exact matches
Recombinant
vaccines rely on one or more
antigens — proteins associated with the
target bacterium — that boost an immune response; in this case Mycobacterium tuberculosis, which causes TB.
The study size requires screening about 10,000 patients for the presence of the MAGE - A3
antigen that the
vaccine targets.
The findings underscore the need for
targeted research to further evaluate manufacturing strategies and
vaccine antigens and platforms, according to the authors.
The Cancer
Vaccine Collaborative is working on treatments that
target multiple cancer
antigens, which should trigger a more aggressive immune response and increase the odds of defeating tumors.
The albumin -
targeted vaccines provoked immune responses five to 10 times stronger than those generated by the peptide
antigens alone.
«In addition, our method offers the potential to accelerate the development of new
vaccines by allowing the efficient evaluation of candidate
target antigens.»
These same models are used to develop new anti-cancer
vaccines based on long peptide or DNA vaccination
targeting the
antigen to
antigen presenting cells.
The overall aim of this project is to determine the functional significance of antibody
targeted cellular and complement responses to a novel pediatric malaria
vaccine candidate
antigen, PfSEA - 1.
These are more specific therapies such as monoclonal antibodies and cancer
vaccines, which
target specific tumor
antigens.
discovery of new
vaccine targets by innovative approaches that allow the identification of non-classical
vaccine antigens like non-protein
antigens and subdominant epitopes and novel protein candidates
Robert Schoen, M.D., M.P.H., of the University of Pittsburgh, presented research showing that the tumor - associated
antigen MUC1 is a promising
target for such a preventative
vaccine.
«This loss - of - HLA mechanism suggests that, when designing
vaccines and cell - based therapies, we need to
target antigens that are presented to the immune system,» says Swanton.
Serogrouping identified isolates expressing capsule
antigens targeted by the
vaccine.
«We have created a potentially much less expensive approach to making a therapeutic cancer
vaccine that, while
targeting a single tumor
antigen, generates an immune response against multiple
antigens.